Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy

NCT07651176 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ENROLLING_BY_INVITATION

Status

267

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Lisaftoclax

Interventions

DRUG: Lisaftoclax+daunorubicin+cytarabine
DRUG: Lisaftoclax+homoharringtonine+cytarabine+aclarubicin
DRUG: Daunorubicin+cytarabine
DRUG: Lisaftoclax+cytarabine
DRUG: Lisaftoclax+azacitidine

Sponsor

First Affiliated Hospital of Zhejiang University